Figure 3From: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib Overall response rate (ORR) and clinical benefit rate (CBR) grouped by the status of PI3K pathway activation. The ORR was marginally significant between pathway activation group and wild type group; the CBR was statistically significant between pathway activation and wild type groups.Back to article page